Knowledge graph · Cancer
Essential Thrombocythemia
hematologic malignancy
- Identifier
- CI-CAN-00002631
- Entity page
- /cancer/essential-thrombocythemia ↗
- Edges
- 152
- Neighbours
- 1 genes2 variants23 drugs10 trials
- Drawn
- 36 of 36 neighbours (cap 60); table lists every fetched edge
Accepted: cancer:<slug>, gene:<symbol>, variant:<slug>, drug:<slug>, trial:<NCT id>, or a bare CI id. Find slugs with search.
Most connectedLung Non-Small Cell Carcinoma 3,147Malignant Colorectal Neoplasm 1,866ABL1 298EGFR 276Imatinib 450Dasatinib 321
Neighbourhood
Radial view
Focus at the centre; neighbours grouped by entity type. Click a node to re-centre the graph on it; ↗ opens the entity page. Hover a spoke for relationship, evidence level, cancer context and source.
Edges
Every edge, grouped by relationship
Source-native edges first (aggregated per neighbour, direction, evidence level and source), then derived registry links. Up to 15 per relationship (10 trials); “show all” raises one group to 200.
| Relationship | Neighbour | Direction | Evidence level | Cancer context | Support | Claim | Source | Expand |
|---|---|---|---|---|---|---|---|---|
| Essential Thrombocythemia approved for …APPROVED_FOR1 of 1 | ||||||||
| ← approved for | Ropeginterferon Alfa-2bother | supports | FDA ORIG | Essential Thrombocythemia | 1 | Regulatory | openfda | graph → |
| Essential Thrombocythemia predicts response to …PREDICTS_RESPONSE_TO1 of 1 | ||||||||
| predicts response to | ||||||||